• Login
  • Register
  • Search

Study on the Mechanism of Liuwei Dihuang Pill Improving the Symptoms of Parkinson’s Disease

Yuxiong Luo, Yongguang Huang, Shilong Xu, Shuai Zhang

Abstract


Aim of the study: The progressive loss of dopaminergic neurons in the m idbrain subst antia nigra pars compacta (SNpc) is the main pathological feature of Parki nson’s disease(PD), the motor dysfunction of PD are also related to it, and the reason is that the neuron-specifi c loss of autophagy leads to the accumulation of misfolded α-synuclein(α-syn) protein aggregates and cell apoptosis. The experiment made by the research group is aimed at obtaining the results of the α-syn,autophagy- inducing, and anti-apoptosis eff ects of Liuwei Dihuang Pill(LDP) to evaluate any potential antiparkinsonian properties to provide the favorable eff ects on motor symptoms in rotenone-i nduced PD rat models.Materials and methods: rotenone-induced PD rat models were
treated with LDP, the behavioral changes of the rats were detected by the bar test and the narrow beam test, the protein levels of
α-syn,autophagy-related proteins(LC3B-II/LC3B-I, P62), and apoptosis-rela ted proteins (Bcl-2/ Bax) were measured using
western blot assays.Results and conclusions: It was observed in the model group compared with the control group that LDP im-
proved the behavioral winch including the bar test and the narrow beam test, reduced the co ntent of α-syn, increased the i nduction of autophagy, and reduced the cel l apoptosis. This study suggests that LDP eff ectively improved the behavioral and dopaminergic neuron damage in rotenone-induced PD rat models, and the mechanism of this action may be increased the induction of autophagy and the relief of apoptosis.

Keywords


Parkinson’s disease; Liuwei Dihuang P ill; Motor symptoms; Autophagy; Apoptosis.

Full Text:

PDF

Included Database


References


[1] Tysnes, O.-B; Storstein, A. Epidemiology of Parkinson’s disease. J Neural Transm. 2017 08;124(8):901-905.

[2] Kowal, SL; Dall, TM; Chakrabarti, R; Jain, A; et al. The current and projected economic burden of Parkinson’s disease in the United States. Mov Disord. 2013 Mar;28(3):311-8.

[3] GBD 2016 Parkinson’s Disease Collaborators. Global, regional, and national burden of Parkinson’s disease, 1990-2016: a system-atic analysis for the Global Burden of Disease Study 2016. Lancet Neurol.2018 11 ;17(11):939-953.

[4] XU Ning-yang;REN Lu;YANG Guan-lin et al. Research on the treatment of blood vessel disease based on the theory of kidney brain integration. China Journal of Traditional Chinese Medicine and Pharmacy. 2022 2; 37(2): 601-604.

[5] CHEN Ya-li; YU-Song; WANG Xu; et. Research on the correlation between Parkinson’s disease and “Kidney-brain Interaction” theory. Global Traditional Chinese Medicine. 2018(4): 574-576.

[6] Dong Meng-jiu; Wang Zai-cao; Wu Zhong-bing. Clinical experience of Liuwei Dihuang Pill in the treatment of Parkinson’s disease. Liaoning Journal of Traditional Chinese Medicine. 2010; 37(1): 34-34.

[7] Zhang, ZN; Zhang, JS; Xiang, J ;et. Subcutaneous rotenone rat model of Parkinson’s disease: Dose exploration study. Brain Res.2017 01 15 ;1655:104-113

[8] Luciani, KR; Frie, JA; Khokhar, JY. An Open-Source Automated Bar Test for Measuring Catalepsy in Rats. eNeuro. 2020; 7(3).

[9] Allbutt HN; Henderson JM. Use of the narrow beam test in the rat, 6-hydroxy dopamine model of Parkinson’s disease. J Neurosci Methods, 2007, 159: 195-202.

[10] Bloem, BR; Okun, MS; Klein, C. Parkinson’s disease. Lancet. 2021 Jun 12;397(10291): 2284-2303.

[11] Postuma, R.; Berg, D.; Stern, M.; Poewe, W.; Olanow, C. MDS clinical diagnostic criteria for Parkinson’s disease. Mov. Disord.2015, 30, 1591–1601.

[12] Cheng, H.-C.; Ulane, C.M.; Burke, R.E. Clinical progression in Parkinson’s disease and the neurobiology of axons. Ann. Neurol.2010, 67, 715–725.

[13] Bridi, JC; Hirth, F; Mechanisms of α-Synuclein Induced Synaptopathy in Parkinson’s Disease. Front Neurosci. 2018;12:80. 2022 ǀ Volume 6 ǀ Issue 17 - 21.

[14] Motyl, JA ; Strosznajder, JB; Wencel, A ; Strosznajder, RP . Recent Insights into the Interplay of Alpha-Synuclein and Sphingo-lipid Signaling in Parkinson’s Disease. Int J Mol Sci.2021 Jun 11 ;22(12).

[15] Moors, TE; Hoozemans, JJ; Ingrassia, A; van de Berg, WD; et al. Therapeutic potential of autophagy-enhancing agents in Parkinson’s disease. Mol Neurodegener.2017 01 25 ;12(1):11

[16] Kabeya, Y; Mizushima, N; Ueno, T; Yoshimori, T; et al. LC3, a mammalian homologue of yeast Apg8p, is localized in autopha-gosome membranes after processing. EMBO J.2000 Nov 01 ;19(21):5720-8.

[17] Y. Ichimura, E. Kominami, K. Tanaka, M. Komatsu, Selective turnover of p62/ A170/SQSTM1 by autophagy. Autophagy. 2008 Nov; 4(8): 1063-1066.

[18] Sahani, MH; Itakura, E; Mizushima, N. Expression of the autophagy substrate SQSTM1/p62 is restored during prolonged starvation depending on transcriptional upregulation and autophagy-derived amino acids. Autophagy.2014 Mar;10(3): 431-441.

[19] Simon, DK; Tanner, CM; Brundin, P. Parkinson Disease Epidemiology, Pathology, Genetics, and Pathophysiology. Clin Geriatr Med.2020 02 ;36(1): 1-12.

[20] Singh, R; Letai, A; Sarosiek, K. Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins. NatRev Mol Cell Biol.2019 03; 20(3): 175-193.

[21] De Falco, M; De Luca, L; Acanfora, F; De Luca, A; et al. Alteration of the Bcl-2: Bax Ratio in the placenta as pregnancy proceeds. Histochem J. 2001 Jul; 33(7): 421-425.




DOI: http://dx.doi.org/10.18686/ahe.v6i17.5452

Refbacks